, Singapore
181 views
Photo from SCG Cell Therapy Pte Ltd

SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement

The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.

SCG Cell Therapy (SCG) and the Agency for Science, Technology and Research (A*STAR) have launched joint laboratories to produce novel cell therapies that meet good manufacturing practice (GMP) standards.

With a combined funding of almost $30m, the partnership will focus on induced pluripotent stem cell (iPSC) technology and develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates.

"The discovery of iPSCs has revolutionised regenerative medicine, offering the potential for standardised, off-the-shelf cell therapies.” Koh Boon Tong, Executive Director, A*STAR's BTI, said.

ALSO READ: NUH to establish health centre for early cancer detection in 2025

The joint laboratories are established at SCG’s GMP facility and A*STAR’s research facility.

Meanwhile, the two organisations also plan to establish a talent development programme to conduct training following current GMP and regulatory requirements.

 

Join Singapore Business Review community

Follow the link for more news on

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Top News

Mi Material launches $215m IPO amidst Asia, US expansion plans
The company plans to establish an R&D and demo centre in Texas.Semiconductor materials unit Mi Material Holding Ltd has launched a $215m initial public offering (IPO) on the Singapore Exchange (SGX) Mainboard to support its expansion plans across Asia and the United States (US).
Markets
Maybank deploys AI to prevent banking disruptions
ServiceNow will support technology monitoring across Malaysia, Singapore, and Indonesia under a five-year agreement.

Exclusives

Singapore opens door to foreign stablecoins under tighter rules
Banks may need separate companies to issue stablecoins under the proposed framework.
Singapore's most notable architecture professionals under 40 of 2026
The honourees span five firms, with women in the majority and a combined portfolio that includes a $960m hospital campus.